S
SVE
vs
W
WIG20
Over the past 12 months, SVE has underperformed WIG20, delivering a return of -25% compared to the WIG20's +29% growth.
Stocks Performance
SVE vs WIG20
Performance By Year
SVE vs WIG20
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Synthaverse SA
Glance View
Biomed Lublin Wytwornia Surowic i Szczepionek SA engages in the manufacture of pharmaceutical products. The company is headquartered in Lublin, Woj. Lubelskie and currently employs 234 full-time employees. The company went IPO on 2011-07-29. The firm focuses on the production of drugs in the field of immunotherapy. Synthaverse SA offers its services in the field such as: oncological immunotherapy, Immunotherapy in Serological Conflict, Passive immunotherapy in hepatitis B, Active anti-tuberculosis immunotherapy, Gynecology and Proctology, Probiotics, Laboratory reagents. The firm offers injection drugs, lyophilisates of active substances in sterile sealed vials, active substances and drugs based on surface and submerged biological culture, suppository forms of drugs. The firm supplies its products to 50 countries around the world.
